Can You Prescribe Foundayo as an FNP in Louisiana?
Yes, as a Family Nurse Practitioner in Louisiana, you can prescribe Foundayo (orforglipron) for weight management, provided you have prescriptive authority under Louisiana state law and the patient meets FDA-approved indications.
Prescriptive Authority Context
Louisiana law grants FNPs with collaborative practice agreements prescriptive authority that includes FDA-approved medications. Foundayo received FDA approval in April 2026 for long-term weight management 1, making it a legitimate prescription option within your scope of practice.
FDA-Approved Indications for Foundayo
You may prescribe Foundayo for 1:
- Adults with obesity (BMI ≥30 kg/m²), OR
- Adults with overweight (BMI 27-29.9 kg/m²) who have at least one weight-related comorbid condition such as:
- Hypertension
- Dyslipidemia
- Obstructive sleep apnea
- Cardiovascular disease
- Type 2 diabetes
Must be used in combination with reduced-calorie diet and increased physical activity 1.
Critical Contraindications - Screen Before Prescribing
Absolute contraindications 1:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Previous serious allergic reaction to orforglipron
Relative contraindications/cautions 1:
- History of pancreatitis
- Severe gastroparesis or delayed gastric emptying
- Diabetic retinopathy (monitor closely)
- Severe renal or hepatic impairment
- Planned surgery requiring anesthesia (inform surgical team)
Dosing and Administration
Foundayo is taken once daily orally, with or without food 1. Tablets must be swallowed whole (not crushed, broken, or chewed). The medication requires dose escalation to minimize gastrointestinal side effects, though specific titration schedules should follow FDA labeling 1.
If 7 or more consecutive doses are missed, restart at a lower dosage with re-escalation 1.
Special Prescribing Considerations
Contraception Requirements
Critical: Foundayo may reduce efficacy of oral hormonal contraceptives 1. For women of childbearing potential using oral contraceptives:
- Switch to non-oral contraceptive method, OR
- Add barrier method for 30 days after initiation and 30 days after each dose escalation 1
Pregnancy
- Advise patients to use effective contraception during treatment
- Inform patients of potential fetal risk
- A pregnancy exposure registry exists (1-800-LillyRx) 1
- Discontinue if pregnancy occurs
Drug Interactions
Monitor patients taking 1:
- Insulin or sulfonylureas (increased hypoglycemia risk)
- Other GLP-1 receptor agonists (do not combine)
Expected Efficacy
Clinical trial data demonstrates substantial weight loss 1:
- Without diabetes: 7.4-11.1% body weight reduction at 72 weeks (vs. 2.1% placebo)
- With type 2 diabetes: 5.1-9.6% body weight reduction at 72 weeks (vs. 2.5% placebo)
- ≥5% weight loss achieved in 47-72% of patients depending on dose
- ≥10% weight loss achieved in 23-55% of patients depending on dose
Common Adverse Effects
Most common side effects are gastrointestinal 1, 2:
- Nausea and vomiting (typically mild-to-moderate)
- Abdominal pain
- Diarrhea
Serious but less common risks 1:
- Pancreatitis
- Gallbladder disease
- Acute kidney injury
- Hypoglycemia (especially with concomitant diabetes medications)
Clinical Positioning
Foundayo represents the first oral GLP-1 receptor agonist approved for weight management 3. Current AGA guidelines recommend GLP-1 receptor agonists (specifically injectable semaglutide 2.4 mg and liraglutide 3.0 mg) as preferred agents for obesity pharmacotherapy due to magnitude of benefit 4. While Foundayo offers an oral alternative for patients who prefer non-injectable therapy 5, injectable GLP-1 receptor agonists may achieve greater weight loss based on comparative data 6.
Consider Foundayo when:
- Patient strongly prefers oral over injectable therapy
- Patient meets FDA-approved indications
- No contraindications exist
- Patient can afford medication (insurance coverage may be limited)
Documentation Requirements
Document in medical record:
- BMI calculation and weight-related comorbidities
- Screening for MTC/MEN 2 family history
- Contraception counseling for women of childbearing potential
- Discussion of risks, benefits, and alternatives
- Lifestyle modification plan (diet and exercise)
- Monitoring plan for adverse effects
Practical Barriers
Be aware that 7:
- Medicare excludes coverage for FDA-approved anti-obesity medications for obesity diagnosis alone
- Medication costs may be substantial
- Supply shortages have affected GLP-1 receptor agonist availability
Bottom line: You have legal authority to prescribe Foundayo in Louisiana as an FNP, but ensure patients meet FDA indications, screen for contraindications (especially MTC/MEN 2), counsel about contraception interactions, and document appropriately.